Monopar Therapeutics’ mission is to developing innovative drug combinations to improve clinical outcomes in advanced cancer.
Monopar is building a drug development pipeline through the licensing or acquisition of oncology therapeutics at the late preclinical through advanced clinical development stage that have demonstrated good antitumor efficacy and safety when used in combination, de-risking clinical development.
Monopar’s lead second drug product candidate, MNPR-101 (huATN-658), is entering clinical development in collaboration with Cancer Research UK.
To contact Monopar about a potential partnership, collaboration, or licensing opportunity, please contact .
Learn more about the first drug development partnership with Cancer Research UK